<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab4">
 <label>Table 4</label>
 <caption>
  <p>Nano-based vaccine candidates to prevent COVID-19 infection</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="left">Name</th>
    <th align="left">Developer</th>
    <th align="left">Method/platform</th>
    <th align="left">Development phase</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left">Moderna coronavirus vaccine</td>
    <td align="left">National Institutes of Health (NIH) and Moderna (United States)</td>
    <td align="left">mRNA-based vaccine, which encodes the full-length of the spike (S) protein encapsulated in lipid nanoparticles</td>
    <td align="left">
     <p>Phase 1</p>
     <p>NCT04283461</p>
     <p>Phase 2</p>
     <p>NCT04405076</p>
    </td>
   </tr>
   <tr>
    <td align="left">NVX-CoV2373</td>
    <td align="left">Novavax, Inc. (United States)</td>
    <td align="left">Virus-like nanoparticle, which contains SARS-CoV-2 S protein combined with adjuvant matrix -M</td>
    <td align="left">Pre-clinical</td>
   </tr>
   <tr>
    <td align="left">Ad5-nCoV</td>
    <td align="left">Cansino Biologics, Inc. (China)</td>
    <td align="left">Adenovirus 5 vector, which contains SARS-CoV-2 S nanoparticles produced in the baculovirus insect cell expression system</td>
    <td align="left">
     <p>Phase I</p>
     <p>NCT04313127</p>
    </td>
   </tr>
   <tr>
    <td align="left">COVID-19 vaccine candidate</td>
    <td align="left">BioNTech/Fosun Pharma/Pfizer (Germany)</td>
    <td align="left">Lipid-based nanoparticles (LNPs) combined with mRNA.</td>
    <td align="left">
     <p>Phase I/II</p>
     <p>NCT04368728</p>
    </td>
   </tr>
   <tr>
    <td align="left">COVID-19 vaccine candidate</td>
    <td align="left">Viroclinics Xplore (Netherlands)</td>
    <td align="left">UQ`S molecular clamp technology, which locks the S protein conformation to mimic the protein found on the live virus</td>
    <td align="left">Pre-clinical</td>
   </tr>
   <tr>
    <td align="left">COVID-19 vaccine candidate</td>
    <td align="left">Ufovax, LLC (United States)</td>
    <td align="left">Virus-like particle with features of SARS-CoV-2 S protein protruding from a protein nanoparticle scaffold</td>
    <td align="left">Pre-clinical</td>
   </tr>
   <tr>
    <td align="left">COVID-19 vaccine candidate</td>
    <td align="left">Janssen Pharmaceuticals, Inc. (Belgium)</td>
    <td align="left">Recombinant vaccine using AdVac
     <sup>®</sup> technology, which is based on the development and production of adenovirus vectors (gene carriers) combined with the PER.C6
     <sup>®</sup> cell line
    </td>
    <td align="left">Pre-clinical</td>
   </tr>
   <tr>
    <td align="left">COVID-19 vaccine candidate</td>
    <td align="left">Translate Bio/Sanofi Pasteur (United States)</td>
    <td align="left">LNPs loading mRNA encoding functional proteins from SARS-CoV-2</td>
    <td align="left">Pre-clinical</td>
   </tr>
   <tr>
    <td align="left">DPX-COVID-19</td>
    <td align="left">IMV, Inc. (Canada)</td>
    <td align="left">LNPs formulated with DPX platform, containing peptides epitopes from SARS-CoV-2 S protein</td>
    <td align="left">Pre-clinical</td>
   </tr>
   <tr>
    <td align="left">COVID-19 vaccine candidate</td>
    <td align="left">CanSino Biologics/Precision NanoSystems (China/Canada)</td>
    <td align="left">LNPs combined with mRNA</td>
    <td align="left">Pre-clinical</td>
   </tr>
   <tr>
    <td align="left">COVID-19 vaccine candidate</td>
    <td align="left">Fudan University/Shanghai JiaoTong University/RNACure Biopharma (China)</td>
    <td align="left">LNPs loading mRNA encoding the receptor-binding domain of SARS-CoV-2 S protein</td>
    <td align="left">Pre-clinical</td>
   </tr>
   <tr>
    <td align="left">COVID-19 vaccine candidate</td>
    <td align="left">Fudan University/Shanghai JiaoTong University/RNACure Biopharma (China)</td>
    <td align="left">LNPs loading mRNA that induces the formation of virus-like particles similar to native SARS-CoV-2 in the host</td>
    <td align="left">Pre-clinical</td>
   </tr>
   <tr>
    <td align="left">COVID-19 vaccine candidate</td>
    <td align="left">University of Tokyo/Daiichi-Sankyo (Japan)</td>
    <td align="left">LNPs combined with mRNA</td>
    <td align="left">Pre-clinical</td>
   </tr>
   <tr>
    <td align="left">COVID-19 vaccine candidate</td>
    <td align="left">BIOCAD (Russia)</td>
    <td align="left">LNPs formulated with recombinant vesicular stomatitis virus (rVSV) that expresses mRNA from SARS-CoV-2</td>
    <td align="left">Pre-clinical</td>
   </tr>
   <tr>
    <td align="left">COVID-19 vaccine candidate</td>
    <td align="left">St. Petersburg Scientific Research Institute of Vaccines and Serums (Russia)</td>
    <td align="left">LNPs formulated with recombinant S protein and other epitopes from SARS-CoV-2</td>
    <td align="left">Pre-clinical</td>
   </tr>
   <tr>
    <td align="left">COVID-19 vaccine candidate</td>
    <td align="left">LakePharma, Inc. (United States)</td>
    <td align="left">Recombinant vaccine containing COVID-19 S proteins created using CHO manufacturing platforms</td>
    <td align="left">Pre-clinical</td>
   </tr>
  </tbody>
 </table>
</table-wrap>
